1. Home
  2. ACXP vs COEP Comparison

ACXP vs COEP Comparison

Compare ACXP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACXP
  • COEP
  • Stock Information
  • Founded
  • ACXP 2017
  • COEP 2017
  • Country
  • ACXP United States
  • COEP United States
  • Employees
  • ACXP N/A
  • COEP N/A
  • Industry
  • ACXP Biotechnology: Pharmaceutical Preparations
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ACXP Health Care
  • COEP Health Care
  • Exchange
  • ACXP Nasdaq
  • COEP Nasdaq
  • Market Cap
  • ACXP 31.4M
  • COEP 32.4M
  • IPO Year
  • ACXP 2021
  • COEP N/A
  • Fundamental
  • Price
  • ACXP $0.76
  • COEP $11.50
  • Analyst Decision
  • ACXP Strong Buy
  • COEP
  • Analyst Count
  • ACXP 1
  • COEP 0
  • Target Price
  • ACXP $12.00
  • COEP N/A
  • AVG Volume (30 Days)
  • ACXP 273.8K
  • COEP 136.7K
  • Earning Date
  • ACXP 03-14-2025
  • COEP 03-25-2025
  • Dividend Yield
  • ACXP N/A
  • COEP N/A
  • EPS Growth
  • ACXP N/A
  • COEP N/A
  • EPS
  • ACXP N/A
  • COEP N/A
  • Revenue
  • ACXP N/A
  • COEP N/A
  • Revenue This Year
  • ACXP N/A
  • COEP N/A
  • Revenue Next Year
  • ACXP N/A
  • COEP N/A
  • P/E Ratio
  • ACXP N/A
  • COEP N/A
  • Revenue Growth
  • ACXP N/A
  • COEP N/A
  • 52 Week Low
  • ACXP $0.68
  • COEP $2.31
  • 52 Week High
  • ACXP $3.35
  • COEP $13.70
  • Technical
  • Relative Strength Index (RSI)
  • ACXP 44.22
  • COEP 57.31
  • Support Level
  • ACXP $0.75
  • COEP $8.65
  • Resistance Level
  • ACXP $0.82
  • COEP $11.75
  • Average True Range (ATR)
  • ACXP 0.05
  • COEP 2.11
  • MACD
  • ACXP 0.01
  • COEP -0.28
  • Stochastic Oscillator
  • ACXP 29.23
  • COEP 53.32

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Share on Social Networks: